Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > Maybe they should buy the patented drugs for 500 % more...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by GenericAdvocateon Oct 25, 2016 12:42pm
77 Views
Post# 25383132

RE:RE:Maybe they should buy the patented drugs for 500 % more...

RE:RE:Maybe they should buy the patented drugs for 500 % more...
ConfidentDD wrote: Um, they did, Donnatol et al. Gosh you are numb!
fundtrader wrote: I think that would be much better..




Donnatal is likely the next shoe to be dropped.   They did not submit the supplemental data that the fda requested.  And the Jesus of the fda didn't like that in my opinion. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities